Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
Portfolio Pulse from
Silo Pharma has initiated a pharmacokinetic and tolerability study for its novel non-opioid pain therapeutic, SP-26, targeting chronic pain and fibromyalgia. This marks a key preclinical milestone for the company.
December 18, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma has started a pharmacokinetic and tolerability study for SP-26, a non-opioid pain therapeutic. This is a significant preclinical milestone for the company.
The initiation of the study represents progress in Silo Pharma's development pipeline, potentially increasing investor confidence and interest. As a developmental stage company, such milestones are crucial for future growth and valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100